Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $16.00 at Canaccord Genuity Group

Niagen Bioscience (NASDAQ:NAGE) had its price target raised by Canaccord Genuity Group from $13.00 to $16.00 in a report published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Other research analysts have also recently issued reports about the company. Roth Capital reaffirmed a “buy” rating and issued a $23.00 target price (up from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Wall Street Zen cut Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th.

Niagen Bioscience Stock Performance

Shares of NAGE stock opened at $14.14 on Tuesday. The company’s 50 day moving average is $9.11. The firm has a market capitalization of $1.11 billion, a P/E ratio of 83.18 and a beta of 2.08. Niagen Bioscience has a 12 month low of $2.31 and a 12 month high of $14.49.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.